Deaths in Novartis CAR-T trial spark autoimmune risk debate
Report says deaths in Novartis’ CAR-T trial are driving debate over acceptable risk levels in autoimmune disease.
Site Search
Search market news
Find public news by keyword, exact ticker, category and date.
Matching instruments
Open a ticker page for its news coverage. The news search below stays a text search.